Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) almost screens out as though it was being acquired. How many times does non-buyout news drive gains north of 70%? In emerging pharma and biotech, it happens more than in other sectors. The news this morning is that Merck KGaA has signed a global agreement with Threshold to co-develop and commercialize Phase 3 Hypoxia-Targeted drug TH-302, which is Threshold’s small molecule hypoxia-targeted drug.
As far as what this translates to, Threshold will receive $25 million as an upfront payment and it is set to receive further milestone payments and royalty payments upon certain targets being achieved. With a market cap of only $63 million and with a recent cash balance of only about $25 million ahead of the news, this is driving home for speculative traders.
After closing at $1.29, the stock’s pre-market surge is a whopping 77% at $2.28. Threshold has a 52-week trading range of $1.20 to $3.34. Threshold has no product revenues as of yet. We have also already seen over 300,000 shares trade hands in the pre-market and the average daily volume is only 136,000 shares.
JON C. OGG
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks